Regeneron Pharmaceuticals: COVID-19 trials

The registry lists 12 COVID-19 studies with Regeneron Pharmaceuticals as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 5Phase 2 5Phase 3 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe DiseaseTerminatedNCT05081388Phase 1/2Results posted
• A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and AdultsTerminatedNCT05074433Phase 3Results posted
• COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of AgeTerminatedNCT04992273Phase 2Results posted
• COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 InfectionCompletedNCT04666441Phase 2Results posted
• COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR AssayCompletedNCT04452318Phase 3Results posted
• Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19CompletedNCT04426695Phase 1/2Results posted
• Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19TerminatedNCT04425629Phase 3Results posted
• Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19CompletedNCT04315298Phase 2/3Results posted
• A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult ParticipantsCompletedNCT05505448Phase 1
• COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult VolunteersCompletedNCT05181683Phase 1
• COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19TerminatedNCT05092581Phase 1
• Compassionate Use of REGN-COV2 for the Treatment of COVID-19No longer availableNCT04617535